The Valley Desk

Clinical trial reportNature medicinePublished

Ciltacabtagene autoleucel in high-risk smoldering multiple myeloma: the CAR-PRISM phase 2 trial

12 of 42 authors shown in byline order.

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Nature medicine
Published
Subject terms
Humans; Multiple Myeloma; Neoplasm, Residual; Immunotherapy, Adoptive; Aged; Middle Aged; Female; Male; Smoldering Multiple Myeloma; Receptors, Chimeric Antigen
PubMed ID
42010117
PubMed Central ID
PMC13375535
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal